Genitourinary Syndrome of Menopause in Cancer Survivors
In this review, we cover important considerations in the assessment of GSM; nonpharmacologic, behavioral, integrative, pharmacologic, and medical device treatments for GSM: the unique considerations in GSM by cancer treatment...
The number of cancer survivors is increasing, and the unique aspects of management of genitourinary syndrome for cancer survivors, such as the safety of hormonal therapies, is important to understand.
Share
Fezolinetant: a Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769482/
The most common symptom of menopause is vasomotor symptoms (VMS), which occur in more than 80% of postmenopausal women. Furthermore, VMS are the manifestation of menopause for which women most...
As early as 4 weeks from initiating fezolinetant, women experienced a statistically significant reduction of both severity and frequency of VMS per day.
Share
The Association of Menopause With Cardiometabolic Disease Risk Factors in Low- and Middle-Income Countries: a Systematic Review and Meta-Analyses
This study aimed to evaluate evidence from the literature on differences in CMD risk factors between premenopausal and postmenopausal midlife women living in low- and middle-income countries.
Compared with premenopausal women, the postmenopausal stage was associated with metabolic syndrome, high waist-to-hip ratio, hypertension, elevated triglycerides, and elevated plasma glucose.
Share
Bone Mineral Density and Trabecular Bone Score Changes Throughout Menopause in Women With HIV
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10747369/
The objectives of this study were to describe the trajectories of bone mineral density (BMD) and trabecular bone score (TBS) changes throughout pre-menopause (reproductive phase and menopausal transition) and post-menopause...
These results suggested that bone health should be assessed with BMD and TBS simultaneously, as they were associated with different risk factors. Both these biomarkers significantly decreased over time throughout the menopausal periods.
Share
Efficacy and Safety of Fezolinetant, a Neurokinin-3 Antagonist, in Treating Vasomotor Symptoms in Postmenopausal Women: a Systematic Review and Meta-Analysis
Source : https://pubmed.ncbi.nlm.nih.gov/38115258/
Fezolinetant can be a treatment option for postmenopausal VMS but warns of a risk increase in endometrial hyperplasia or tumors.
The results of this study bring to light the effectiveness of fezolinetant as a treatment option, especially for patients at risk of breast cancer and other contraindications of hormone therapy.
Share